Sign In

Lung Cancer

Imfinzi Improves Overall & Progression-Free Survival for Patients With Limited-Stage Small Cell Lung Cancer

Tarlatamab: A New Therapy Approved for Small-Cell Lung Cancer

Osimertinib: A New Standard of Care for Stage III EGFR-Mutated Non-Small Cell Lung Cancer

Biomarker Testing in Lung Cancer — It Must Be Standard Of Care

Tepmetko Approval for NSCLC Mutation Underscores the Value of Genetic Testing

Physicians Advised to Consider Rybrevant for EGFR Mutation-Positive NSCLC, Following FDA Approval

Immunotherapy Drug Imfinzi Plus Chemotherapy Boosts Survival Rates In Metastatic Lung Cancer Patients: New Study

Latest Outcomes from the PACIFIC Trial Suggest Overall Survival Improvement for Lung Cancer

‘Practice Changing’ Trial Results Suggest Tagrisso Can Delay Recurrence of EGFR Mutated Lung Cancer

Study Raises Clinical Considerations for Strategic Immunotherapy Use in Metastatic Cancer Care

Decision Making Between Second- and Third-Generation ALK Inhibitors for Lung Cancer

Could Durvalumab (Imfinzi) Improve Survival in Early-Stage NSCLC?

Unprecedented Progression-Free Survival for ALK-Positive Non-Small Cell Lung Cancer Using Lorbrena — What the New Research Means for Patients

Is a CT Scan Always Needed After Chemoradiation for Lung Cancer?

Dr. Balazs Halmos, UCLA Medical Center

‘Great Urgency’ to Understand KRAS as an Actionable Marker in Lung Cancer

Dr. Balazs Halmos, UCLA Medical Center

Lung Cancer — The Nuances of Mutations & Targeted Therapies

Patient Care Updates

Importance of Monitoring Lung Cancer Patients on Imfinzi for Possible Pneumonitis

Predicting Which Lung Cancer Patients Will Benefit From Immunotherapy

Targeted Therapies Offer Greater Precision in Advanced Lung Cancer Treatment

Metastatic Lung Cancer – Deciding on Next Steps

Immunotherapy for Lung Cancer - It's Not for Everyone

Enhertu Approval: New Opportunities for Antibody-Drug Conjugates in Lung Cancer Therapy